Delivery Order SPE2DB20D2014-SPE2DB25FC13F
- Not listed
- AmerisourceBergen Drug Corp received a competitive delivery order award from the Defense Logistics Agency (DLA) valued at $8,291.76 for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product for immunological conditions. The contract is unclassified as a set-aside and carries a firm fixed-price structure with an ultimate completion date of September 8, 2025. The place of performance is located in Conshohocken, Pennsylvania, the company's corporate headquarters, where...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on April 21, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a prescription immunosuppressant medication used to treat autoimmune diseases. This firm fixed-price delivery order, valued at $25,463.41, represents a non-competitive set-aside award with an ultimate completion date of April 22, 2025, and will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. The award...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on May 22, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mls, a biologic medication used to treat inflammatory conditions. This is a firm fixed-price delivery order with a ceiling value of $4,531.80 and an ultimate completion date of May 23, 2025. The contract is non-competitive with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $8,967.32 by the Defense Logistics Agency's Medical Supply Chain on June 25, 2025, for the supply of HUMIRA Pen 40mg/4ml in a quantity of two units. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open competition. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- AmerisourceBergen Drug Corp was awarded a $2,570.10 delivery order by the Defense Logistics Agency on June 9, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. This firm fixed-price, non-set-aside delivery order is scheduled for completion by June 10, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract represents a child...
- The Defense Logistics Agency awarded a $63,341.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies. The contract was competitively awarded without set-aside provisions and is scheduled for completion by September 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on September 17, 2025, for the supply of HUMIRA(CF) Pen 40 mg/0.4 mls, a prescription immunosuppressant medication. The contract carries a ceiling value of $5,281.33 and features firm fixed-price pricing with an ultimate completion date of September 18, 2025. This is a non-set-aside award, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this contract. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp was awarded a $30,792.85 delivery order contract for HUMIRA Pen 40mg/4mL (2-pack units) under a firm fixed-price arrangement with an ultimate completion date of September 4, 2025. This competitively awarded, non-set-aside delivery order is issued by the Defense Logistics Agency's Medical Supply Chain, which procures pharmaceutical and medical products to support the Department of Defense's healthcare operations, including military treatment facilities and the...
- The U.S. Defense Logistics Agency Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, in the amount of $10,633.60 for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical products. This delivery order contract has a completion date of February 6, 2024 and was awarded on February 5, 2024. Amerisourcebergen Drug Corp is the prime contractor on this award, which does not utilize any...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC13FDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for $1,132.95 to supply HUMIRA (CF) Pen 40 mg/0.4 mls, a brand-name pharmaceutical product used in the treatment of autoimmune conditions. The contract is a firm fixed-price delivery order with an ultimate completion date of June 6, 2025, and was competitively awarded without set-aside designation. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The SPE2DX contract serves as a critical supply mechanism for the Defense Health Agency and other federal healthcare systems, enabling AmerisourceBergen to fulfill a wide spectrum of pharmaceutical and medical supply requirements on a global basis. As the prime contractor under this vehicle, AmerisourceBergen has demonstrated its capability to meet federal procurement standards through multiple competitive awards encompassing diverse therapeutic domains, including specialty medications, vaccines, and medical devices. This particular delivery order reflects the company's ongoing role in supporting military and federal healthcare operations through the DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 6/5/25 |